DNMT1 and cancer: Ever since the breakthrough of epigenetics in cancer treatment, several in silico studies such as pharmacophore and QSAR modeling (Yoo, Kim, and Robertson 2012; Phanus-Umporn et al., 2020) have been reported for drug discovery against DNMT1 through small modulators.